Tumor Mutational Burden (TMB)
Immunotherapy Response
This assay improves the prediction of a patient’s response to immunotherapy across various cancer types and assists the physician in selecting the most suitable personalized treatment.Tumor mutation burden (TMB) is an FDA-approved, autonomous predictive biomarker linked to patient responses to immunotherapy.The tumor mutational burden (TMB) denotes the aggregate count of somatic mutations inside a tumor’s genome. cancers exhibiting a high mutation burden may possess an elevated frequency of neoantigens, which, in theory, should be more immunogenic than cancers with a relatively low mutation burden.
Technical Specifications of TMB Assay
The assessment is conducted via the Oncomine™ Tumor Mutation Load Assay, which analyzes 409 genes. This is a comprehensive targeted Next Generation Sequencing (NGS) technique that delivers precise quantification of somatic mutations to evaluate tumor mutation load in formalin-fixed, paraffin-embedded (FFPE) tissues.
For patients whose response to immunotherapy requires exclusive investigation, the Immune Response test is advised, encompassing the three biomarkers TMB, MSI, and PD-L1 for predicting immunotherapy response.
Exemplary Results Report
The examination encompasses all cancer types and enhances the prediction of patients’ responses to immunotherapy.
Results will be accessible within 10 business days, next business day after the sample is delivered to the laboratory.
Payments may be executed via bank transfer or cash.
Please reach out to the Customer service concerning the reception of the sample. The results are communicated to both you and your doctor by email.
